Stock listing

NASDAQ:CNSP CNS Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of CNS Pharmaceuticals, Inc.

Follow CNS Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CNSP

$3.56 USD -0.88 (-19.8%)

Close on Nov 20, 2026

Past year -45.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.56 – $3.68 USDNov 20, 2026
Volume
666 sharesNov 20, 2026
Market cap
$5.25M USDAt the close on Nov 20, 2026 · price × 1.48M shares outstanding
52-week range
$1.90 – $10.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$45,536 USDMedian day 4,400 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
CNS Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CNSP · Home$3.56 USD-0.88 (-19.8%)666$3.678$3.678$3.56$4.44Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CNSP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.56-0.88-19.8%$3.678$3.678$3.56666
$4.44+0.29+7.0%$4.18$4.44$4.163,184
$4.15+0.67+19.3%$3.59$4.395$3.448,311
$3.48+0.59+20.4%$3.14$3.547$2.9628,735
$2.89-0.73-20.2%$3.70$3.70$2.8918,100
$3.620.000.0%$3.70$3.70$3.622,800
$3.62-0.23-6.0%$4.045$4.07$3.624,400
$3.85-0.09-2.3%$3.98$3.98$3.775,900
$3.94+0.02+0.5%$4.091$4.175$3.905,900
$3.92-0.09-2.2%$4.05$4.26$3.8948,400
$4.01-0.33-7.6%$4.07$4.11$4.003,400
$4.34-0.21-4.6%$4.39$4.39$4.064,000
$4.55+0.16+3.6%$4.40$4.70$4.0013,900
$4.39-0.61-12.2%$5.00$5.00$4.29615,100
$5.00+0.23+4.8%$4.60$5.01$4.2552,900
$4.77+0.26+5.8%$4.60$5.19$4.3546,400
$4.51-0.57-11.2%$4.50$5.37$4.3061,100
$5.08+0.455+9.8%$4.68$5.45$4.1175,400
$4.625-0.345-6.9%$4.755$4.755$4.5252,200
$4.97+0.22+4.6%$4.50$5.00$3.676,000
$4.75-0.075-1.6%$4.75$4.95$3.9810,000
$4.825-0.165-3.3%$4.825$4.825$4.825300
$4.990.000.0%$4.99$4.99$4.990
$4.99+0.139+2.9%$4.85$5.00$4.7555,600
$4.851-0.326-6.3%$4.98$5.00$4.6513,400
$5.177-0.173-3.2%$5.177$5.177$5.177900
$5.350.000.0%$5.35$5.35$5.35655
$5.35+0.16+3.1%$5.13$5.40$5.0014,200
$5.19-0.16-3.0%$5.34$5.40$5.036,200
$5.350.000.0%$5.35$5.35$5.341,200
$5.35-0.08-1.5%$5.36$5.36$5.351,800
$5.43+0.128+2.4%$5.35$5.44$5.0822,700
$5.302+0.0020.0%$5.40$5.45$5.3026,200
$5.30-0.025-0.5%$5.50$5.50$5.302,000
$5.325+0.085+1.6%$5.23$5.40$5.1110,900
$5.24-0.06-1.1%$5.35$5.35$5.24900
$5.30+0.393+8.0%$5.25$5.475$4.938,000
$4.907-0.203-4.0%$4.907$4.907$4.907500
$5.11+0.179+3.6%$4.982$5.11$4.972,400
$4.931-0.219-4.3%$5.21$5.21$4.9311,300
$5.150.000.0%$5.15$5.15$5.151,800
$5.15-0.089-1.7%$5.15$5.15$5.152,900
$5.239+0.02+0.4%$5.245$5.245$5.002,700
$5.219+0.109+2.1%$5.12$5.50$5.122,300
$5.11-0.01-0.2%$5.12$5.12$5.064,400
$5.12-0.38-6.9%$5.35$5.35$5.052,600
$5.50-0.20-3.5%$5.54$5.54$5.503,900
$5.700.000.0%$5.70$5.70$5.702,000
$5.70-0.14-2.4%$5.70$5.70$5.701,000
$5.84+0.09+1.6%$5.845$5.845$5.7318,500
$5.75-0.03-0.5%$5.79$5.79$5.751,600
$5.78-0.16-2.7%$5.89$5.94$5.762,700
$5.94+0.21+3.7%$5.64$5.99$5.6410,600
$5.73-0.157-2.7%$5.86$5.916$5.734,800
$5.887-0.123-2.0%$6.00$6.00$5.601,700
$6.01+0.118+2.0%$5.91$6.01$5.74519,700
$5.892-0.088-1.5%$5.77$5.892$5.771,700
$5.98+0.457+8.3%$5.63$5.98$5.615,100
$5.523+0.006+0.1%$5.70$5.79$5.4773,700
$5.517+0.077+1.4%$5.57$5.80$5.507,200
$5.44-0.36-6.2%$5.80$5.81$5.447,000
$5.80-0.14-2.4%$5.74$6.05$5.7398,600
$5.94+0.11+1.9%$5.71$6.19$5.6018,800
$5.83-0.17-2.8%$5.965$6.05$5.838,000
$6.00+0.17+2.9%$5.71$6.076$5.714,100

Splits

4 splits since 2022 · NASDAQ:CNSP · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-50Consolidation
1-for-50Consolidation
1-for-30Consolidation
Ticker
NASDAQ:CNSP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All CNS Pharmaceuticals, Inc. news

CNS Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 172 in all · newest Nov 16, 2026 · oldest 2019
Decks
24 decks · latest Jul 2, 2026

Where CNS Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CNSP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CNSPBOATSUnited StatesUSD
Frankfurt:BE50FrankfurtGermanyEUR

Valuation

Price/book 0.3× against a median of 1.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$11.96M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.74

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CNS Pharmaceuticals, Inc. · NASDAQ:CNSPUS$5.25M−US$11.96Mn/an/an/a0.3×n/a0.0×0.74
Theriva Biologics, Inc. · AMEX:TOVXUS$5.51MUS$461,120n/an/an/a0.5×n/a0.3×2.65
Hemostemix Inc · TSXV:HEMUS$5.35MUS$7.70Mn/an/an/an/an/an/a0.47
Curative Biotechnology Inc · OTC:CUBTUS$5.34MUS$6.55Mn/an/an/an/an/an/a1.27
Abpro Holdings, Inc. · OTC:ABPOUS$5.31MUS$1.07M2.6×n/an/an/an/an/a-0.79
Soligenix, Inc. · NASDAQ:SNGXUS$5.14M−US$3.61Mn/an/an/a0.8×n/a0.0×1.76
Rakovina Therapeutics Inc · TSXV:RKVUS$5.10MUS$7.20Mn/an/an/an/an/an/a-0.43
StimCell Energetics Inc. · OTC:STMEUS$5.10MUS$5.09Mn/an/an/an/an/an/a0.99
Longeveron Inc. · NASDAQ:LGVNUS$5.05M−US$1.78Mn/a−1.5×n/a1.1×n/a0.1×1.55
Oncodesign Precision Medicine S.A. · EURONEXT:ALOPMUS$5.04MUS$8.61M0.8×30.0×0.9×1.2×n/a1.6×n/a
Patrys Limited · ASX:PABUS$4.96MUS$4.47Mn/a8.2×n/a10.2×−363.7%0.0×n/a
Median of the othersUS$5.12MUS$4.78M1.7×8.2×0.9×1.1×−363.7%0.1×1.13

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.65 · 1 analyst

Team and board

Officers

OfficerRole
Rami LevinPresident & Chief Executive Officer
Steve O’LoughlinChief Financial Officer
Dylan WenkeChief Business Officer
Eric FaulknerChief Technology Officer
Lynne KelleyChief Medical Officer

Board

DirectorRole
Faith CharlesChair
Amy MaheryDirector
Bettina M. CockroftDirector
Jeffry R. KeyesDirector
Michal FisherDirector
Rami LevinPresident & Chief Executive Officer

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026+43.6%
Q2 2026Aug 12, 2026 · Before open−2.3%
Q4 2025Mar 31, 2026 · After close−4.8%
Q3 2025Nov 14, 2025 · After close−2.9%
Q2 2025Aug 14, 2025 · After close−15.6%
Q1 2025May 15, 2025 · After close+1.6%
Q4 2024Mar 31, 2025 · Before open+4.6%
Q3 2024Nov 14, 2024 · After close−11.8%
Q2 2024Aug 14, 2024 · After close+1.4%
Q1 2024May 15, 2024 · After close+12.5%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 14, 2024−7.8%
Q3 2023Nov 14, 2023 · After close+15.0%
Q2 2023Aug 14, 2023 · Before open−12.8%
Q1 2023May 15, 2023 · Before open+0.7%
Q4 2022Mar 31, 2023 · After close−2.0%
Q3 2022Nov 10, 2022 · After close+1.6%
Q2 2022Aug 12, 2022 · After close+1.2%
Q1 2022May 13, 2022 · After close−2.1%
Q4 2021Mar 3, 2022 · Before open+10.3%
Quarter to Sep 30, 2021Nov 12, 2021 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck12 slidesJul 2, 2026
Investor Presentation (March 2026)Investor deck12 slidesMarch 2026
Investor Presentation (September 2025)Investor deck20 slidesSeptember 2025
Investor Presentation (July 2025)Investor deck20 slidesJul 15, 2025
Investor Presentation (April 2025)Investor deck21 slidesApril 2025
Investor Presentation (February 2025)Investor deck23 slidesFebruary 2025
Investor Presentation (January 2025)Investor deck23 slidesJan 3, 2025
Investor Day (December 2024)Investor day44 slidesDec 11, 2024
Investor Presentation (October 2024)Investor deck17 slidesOctober 2024
Investor Presentation (April 2024)Investor deck19 slidesApr 15, 2024
All 24 decks
DeckKindSlidesDate
Investor Presentation (January 2022)Investor deck19 slidesJan 10, 2022
Investor Presentation (December 2021)Investor deck23 slidesDec 3, 2021
Investor Presentation (July 2021)Investor deck19 slidesJul 19, 2021
Investor Presentation (May 2021)Investor deck19 slidesMay 18, 2021
Investor Presentation (March 2021)Investor deck19 slidesMar 17, 2021
Investor Presentation (February 2021)Investor deck26 slidesFeb 25, 2021
Investor Presentation (December 2020)Investor deck26 slidesDec 11, 2020
Investor Presentation (September 2020)Investor deck23 slidesSep 16, 2020
Investor Presentation (June 2020)Investor deck23 slidesJun 25, 2020
Investor Presentation (March 2020)Investor deck23 slidesMar 10, 2020
Investor Presentation (January 2020)Investor deck22 slidesJan 13, 2020
IPO Roadshow (October 2019)IPO roadshow39 slidesOct 15, 2019
IPO Roadshow (October 2019)IPO roadshow39 slidesOct 10, 2019
IPO Roadshow (July 2019)IPO roadshow37 slidesJul 16, 2019

Open Decks

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$22.5M · US$2.3 a share · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Buyers: ADAR1 Capital; Ikarian Capital; Stonepine Capital Management; Nazare Partners
Use of proceeds: To identify, acquire and advance differentiated clinical assets, plus working capital and general corporate purposes
May 4, 2026
Public offering of shares of common stock and Series F common stock purchase warrants
Closed: US$5M raised · US$1.265 a share · Warrants at US$1.14 for 60 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Together with cash on hand, to fund planned operations into the second half of 2026
May 16, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$4.00 a share on Nov 7, 2019.

Price
US$4.00 a share
Shares offered
2,125,000 shares of common stock
Offering size
US$850,000
Underwriters' option
Up to 318,750 more shares
Listing
CNSP on the Nasdaq Capital Market
Shares delivered
On or about Nov 13, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceMar 28, 2019
Filed publiclyJun 28, 2019
Amended 3 timesNewest Oct 7, 2019
Shares registered with an exchangeNov 5, 2019
Declared effective by the SECNov 7, 2019
Final prospectus, with the priceNov 8, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Nov 8, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00000000
Cost of revenue3.31K4.13K11.8K13.1K11.1K1.96K
Gross profit-3.31K-4.13K-11.8K-13.1K-11.1K-1.96K
Research and development9.77M9.29M14.1M9.30M9.81M5.06M1.85M21.3K32.6K
Selling, general and administrative6.21M5.61M4.77M5.97M4.68M4.39M1.98M860.5K437.9K
Operating income-16.0M-14.9M-18.9M-15.3M-14.5M-9.45M-3.83M-881.8K-516.3K
Depreciation and amortization3.92K3.31K4.13K11.8K13.1K11.1K1.96K02.34K
EBITDA-16.0M-14.9M-18.9M-15.3M-14.5M-9.44M-3.83M-881.8K-513.9K
Interest expense15.2K16.1K13.8K7.03K9.29K3.26K26.2K28.6K4.26K
Income before tax-15.9M-14.9M-18.9M-15.3M-14.5M-9.46M-3.88M-7.39M-219.4K
Income tax00000000-516.3K
Net income-15.9M-14.9M-18.9M-15.3M-14.5M-9.46M-3.88M-7.39M-526.5K
Earnings per share, basic-35.75-466.89-12,509.11-11.22-16.50-0.57-0.28-0.70
Earnings per share, diluted-35.75-466.89-12,509.11-11.22-16.50-0.57-0.28-0.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents7.20M6.46M548.7K10.1M5.00M14.0M7.24M282.7K110.5K
Receivables0882.5K0
Current assets8.10M8.66M1.59M12.6M7.48M15.5M7.89M588.1K162.2K
Property, plant and equipment18.0K6.00K4.93K5.66K16.1K23.4K18.2K0
Goodwill334.1K
Total assets8.62M8.70M1.70M13.1M8.76M15.9M7.91M683.3K162.2K
Accounts payable3.77M2.20M5.83M3.68M1.98M946.3K243.7K128.1K57.5K
Current liabilities4.10M2.52M6.13M4.92M2.59M1.91M311.0K1.23M220.7K
Total debt328.6K326.1K300.8K410.0K387.8K439.3K316.9K121.8K
Total liabilities4.10M2.52M6.13M4.92M2.59M1.91M311.0K1.23M220.7K
Shareholders' equity4.52M6.18M-4.43M8.13M6.16M13.9M7.60M-549.3K-58.5K
Shares outstanding632.5K117.8K2.49K1.62M949.1K23.9M16.5M16.5M18

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-13.8M-17.1M-14.1M-10.6M-13.5M-7.32M-3.55M-716.4K-112.2K
Capital spending-18.2K-4.19K-3.90K-4.42K-5.75K-17.9K-20.1K0-3
Free cash flow-13.8M-17.1M-14.1M-10.6M-13.5M-7.34M-3.57M-716.4K-112.2K
Cash from investing-18.2K-4.19K-3.90K-4.42K-5.75K-17.9K-20.1K0-20.1K
Cash from financing14.6M23.0M4.64M15.6M4.51M14.1M10.3M1.16M222.7K
Share buybacks-2.04K014.2M10.3M390.5K100.9K
Change in cash739.6K5.91M-9.51M5.05M-9.03M6.80M6.69M444.6K110.5K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportOct 2, 2026Management or board changeSEC
DEFA14A · Additional proxy materialAug 25, 2026Meeting noticeSEC
DEF 14A · Proxy statementAug 21, 2026Meeting noticeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportJul 2, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveMay 27, 2026Other filingsSEC
424B3 · ProspectusMay 26, 2026Offer documentSEC
CORRESP · Letter to the SECMay 22, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 22, 2026Other filingsSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
DMay 19, 2026Other filingsSEC
S-3 · Registration statementMay 19, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026Material contractSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeApr 17, 2026Big-stake noticeSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 11, 2026Current reportSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 4, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Management or board changeSEC
S-8 · Registration statement for employee plansFeb 27, 2026Offer documentSEC
8-K · Current reportFeb 17, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
8-K · Current reportDec 17, 2025Management or board changeSEC
8-K · Current reportNov 21, 2025Management or board changeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialNov 12, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeNov 4, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersOct 27, 2025Annual reportSEC
DEF 14A · Proxy statementOct 24, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 10, 2025Meeting noticeSEC
424B5 · ProspectusSep 19, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportJul 22, 2025Current reportSEC
8-K · Current reportJul 15, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025Material contractSEC
424B4 · ProspectusMay 14, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 14, 2025Other filingsSEC
CORRESP · Letter to the SECMay 12, 2025Other filingsSEC
CORRESP · Letter to the SECMay 12, 2025Other filingsSEC
S-1/A · Registration statement, amendedMay 12, 2025Offer documentSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
CORRESP · Letter to the SECApr 17, 2025Other filingsSEC
CORRESP · Letter to the SECApr 17, 2025Other filingsSEC
CORRESP · Letter to the SECApr 14, 2025Other filingsSEC
CORRESP · Letter to the SECApr 14, 2025Other filingsSEC
S-1 · Registration statementApr 14, 2025Offer documentSEC
UPLOAD · Letter from the SECApr 11, 2025Other filingsSEC
8-K · Current reportApr 9, 2025Current reportSEC
DRSLTR · Letter to the SEC with a draftApr 7, 2025Other filingsSEC
DRS · Draft registration statementApr 7, 2025Offer documentSEC
8-K · Current reportMar 31, 2025Current reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
424B5 · ProspectusMar 20, 2025Offer documentSEC
8-K · Current reportMar 20, 2025Current reportSEC
8-K · Current reportFeb 21, 2025Current reportSEC
8-K · Current reportJan 3, 2025Current reportSEC
8-K · Current reportDec 11, 2024Current reportSEC
8-K · Current reportDec 2, 2024Meeting outcomeSEC
DEFR14ANov 15, 2024Meeting noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 1, 2024Current reportSEC
DEF 14A · Proxy statementOct 28, 2024Meeting noticeSEC
8-K · Current reportOct 24, 2024Material contractSEC
424B5 · ProspectusOct 24, 2024Offer documentSEC
8-K · Current reportOct 23, 2024Current reportSEC
PRE 14A · Preliminary proxy statementOct 15, 2024Meeting noticeSEC
8-K · Current reportSep 18, 2024Current reportSEC
8-K · Current reportSep 12, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024Current reportSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 5, 2024Other filingsSEC
SC 13D · Big-stake noticeAug 2, 2024Big-stake noticeSEC
RW · Request to withdraw a registrationJul 31, 2024Other filingsSEC
424B3 · ProspectusJul 30, 2024Offer documentSEC
8-K · Current reportJul 30, 2024Current reportSEC
8-K · Current reportJul 30, 2024Material contractSEC
424B5 · ProspectusJul 26, 2024Offer documentSEC
8-K · Current reportJul 26, 2024Material contractSEC
8-K · Current reportJul 24, 2024Current reportSEC
S-1/A · Registration statement, amendedJul 19, 2024Offer documentSEC
S-1 · Registration statementJul 12, 2024Offer documentSEC
8-K/A · Current report, amendedJul 11, 2024Current reportSEC
8-K · Current reportJul 9, 2024Current reportSEC
424B5 · ProspectusJul 5, 2024Offer documentSEC
8-K · Current reportJul 3, 2024Material contractSEC
SC 13G · Big-stake noticeJul 2, 2024Big-stake noticeSEC
424B5 · ProspectusJun 27, 2024Offer documentSEC
8-K · Current reportJun 26, 2024Material contractSEC
SC 13G · Big-stake noticeJun 25, 2024Big-stake noticeSEC
8-K/A · Current report, amendedJun 20, 2024Current reportSEC
424B5 · ProspectusJun 17, 2024Offer documentSEC
8-K · Current reportJun 14, 2024Material contractSEC
S-1 · Registration statementJun 7, 2024Offer documentSEC
8-K · Current reportJun 5, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 20, 2024Other filingsSEC
8-K · Current reportMay 16, 2024ResultsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
CORRESP · Letter to the SECMay 15, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 15, 2024Other filingsSEC
S-3 · Registration statementMay 9, 2024Offer documentSEC
8-K · Current reportMay 7, 2024Current reportSEC
8-K · Current reportMay 3, 2024Management or board changeSEC
8-K · Current reportApr 12, 2024Current reportSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
DEF 14A · Proxy statementApr 9, 2024Meeting noticeSEC
8-K · Current reportApr 1, 2024ResultsSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
PRE 14A · Preliminary proxy statementMar 28, 2024Meeting noticeSEC
8-K · Current reportFeb 27, 2024Management or board changeSEC
8-K · Current reportFeb 21, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 6, 2024Insider tradeSEC
8-K · Current reportFeb 2, 2024Material contractSEC
424B4 · ProspectusJan 31, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 30, 2024Other filingsSEC
CORRESP · Letter to the SECJan 26, 2024Other filingsSEC
CORRESP · Letter to the SECJan 26, 2024Other filingsSEC
CORRESP · Letter to the SECJan 25, 2024Other filingsSEC
CORRESP · Letter to the SECJan 25, 2024Other filingsSEC
CORRESP · Letter to the SECJan 24, 2024Other filingsSEC
CORRESP · Letter to the SECJan 24, 2024Other filingsSEC
8-K · Current reportJan 23, 2024Management or board changeSEC
S-1/A · Registration statement, amendedJan 22, 2024Offer documentSEC
CORRESP · Letter to the SECJan 18, 2024Other filingsSEC
CORRESP · Letter to the SECJan 18, 2024Other filingsSEC
CORRESP · Letter to the SECJan 16, 2024Other filingsSEC
CORRESP · Letter to the SECJan 16, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 10, 2024Offer documentSEC
CORRESP · Letter to the SECDec 26, 2023Other filingsSEC
CORRESP · Letter to the SECDec 26, 2023Other filingsSEC
CORRESP · Letter to the SECDec 21, 2023Other filingsSEC
CORRESP · Letter to the SECDec 21, 2023Other filingsSEC
CORRESP · Letter to the SECDec 21, 2023Other filingsSEC
CORRESP · Letter to the SECDec 21, 2023Other filingsSEC
8-K · Current reportDec 21, 2023Current reportSEC
CORRESP · Letter to the SECDec 20, 2023Other filingsSEC
CORRESP · Letter to the SECDec 20, 2023Other filingsSEC
CORRESP · Letter to the SECDec 20, 2023Other filingsSEC
CORRESP · Letter to the SECDec 20, 2023Other filingsSEC
8-K · Current reportDec 18, 2023Current reportSEC
CORRESP · Letter to the SECDec 14, 2023Other filingsSEC
CORRESP · Letter to the SECDec 14, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 13, 2023Other filingsSEC
S-1 · Registration statementDec 8, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 1, 2023Other filingsSEC
424B3 · ProspectusNov 30, 2023Offer documentSEC
CORRESP · Letter to the SECNov 28, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 28, 2023Other filingsSEC
S-8 · Registration statement for employee plansNov 21, 2023Offer documentSEC
S-3 · Registration statementNov 20, 2023Offer documentSEC
8-K · Current reportNov 15, 2023ResultsSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportOct 18, 2023Current reportSEC
8-K · Current reportOct 17, 2023Material contractSEC
4/A · Change in ownership, amendedOct 12, 2023Insider tradeSEC
4/A · Change in ownership, amendedOct 12, 2023Insider tradeSEC
4/A · Change in ownership, amendedOct 12, 2023Insider tradeSEC
4/A · Change in ownership, amendedOct 12, 2023Insider tradeSEC
4/A · Change in ownership, amendedOct 12, 2023Insider tradeSEC
4/A · Change in ownership, amendedOct 12, 2023Insider tradeSEC
4 · Change in ownershipSep 25, 2023Insider tradeSEC
4 · Change in ownershipSep 25, 2023Insider tradeSEC
4 · Change in ownershipSep 25, 2023Insider tradeSEC

This page holds 200 of 391 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CNS Pharmaceuticals, Inc.’s releases · as of Nov 15, 2026

Common shares
1,475,699
Fully diluted
1,475,699

Fully diluted

LineSharesAs of
Common shares1,475,699Nov 15, 2026

Warrants and options

Lot
Warrants · US$1.14 · expire about May 2030

Share count over time

CountShares
Nov 15, 20261,475,699

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ikarian Capital, LLC136K9.2%US$720KSep 30, 2026
ADAR1 Capital Management, LLC70,0004.7%US$371KSep 30, 2026
Stonepine Capital Management, LLC39,9422.7%US$212KSep 30, 2026
Vanguard25,9861.8%US$138KSep 30, 2026
Citadel19,6951.3%US$104KSep 30, 2026
Boothbay Fund Management, LLC13,5240.92%US$71,677Sep 30, 2026
Tower Research Capital LLC (TRC)1500.01%US$795Sep 30, 2026
UBS130<0.01%US$689Sep 30, 2026
Fidelity26<0.01%US$136Sep 30, 2026
Barrett & Company, Inc.8<0.01%US$42Sep 30, 2026
All 12 holders
HolderSharesOf the companyValueAs of
Danske Bank A/S1<0.01%US$5Sep 30, 2026
Barclays1<0.01%US$5Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund6,9930.47%US$33,427Jun 30, 2026
Fidelity Extended Market Index Fund6,7360.46%US$36,644May 31, 2026
Fidelity Series Total Market Index Fund5550.04%US$3,019May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Fisher Michal
Director
Buy2,000USD 5.00US$10,000May 18, 2026
Charles Faith L.
Director
Buy7,100USD 4.79US$34,009May 18, 2026

Big stakes

StakeStakeSharesDateFiling
Ikarian Capital, LLC9.90%147KJun 30, 2026Schedule 13G
Stonepine Capital Management, LLC9.90%160KMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John Climaco
Other companies: Moleculin Biotech, Inc. (Director · Since at least Jul 24, 2017); Essex Rental Corp (Director · Oct 1, 2015 – Oct 1, 2015 · Past); Perma-Fix Environmental Services, Inc. (Director · Jul 1, 2015 – Jul 1, 2015 · Past)
Chief Executive Officer, Director · Since at least Nov 7, 2019
Bettina M. Cockroft
Other companies: Annexon, Inc. (BOARD MEMBER · Since at least Jun 5, 2025)
Director · Since at least Nov 17, 2025
Faith L. Charles
Other companies: Abeona Therapeutics Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Dec 17, 2025
Jeffry R. Keyes
Other companies: Quantum-Si Incorporated (Chief Financial Officer · Since at least May 15, 2023)
Director · Since at least Nov 7, 2019
Steve O'Loughlin
Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Financial Officer · Sep 1, 2021 – Mar 31, 2025 · Past)
Chief Financial Officer · Since at least Mar 2, 2026
Amy MaheryDirector · Since at least Nov 5, 2026
Andrzej AndraczkeDirector · Jul 15, 2021 – Sep 21, 2023 · Past
Carl Anthony EvansDirector · Nov 7, 2019 – Apr 8, 2024 · Past
Dylan WenkeChief Business Officer · Since at least Sep 1, 2026
Eric FaulknerChief Technology Officer · Since at least Feb 17, 2026
All 15 people
PersonSeat
Jerzy GumulkaDirector · Since at least Nov 7, 2019
Lynne KelleyChief Medical Officer · Since at least Mar 2, 2026
Michal FisherDirector · Since at least May 4, 2026
Rami LevinPresident & Chief Executive Officer · Since at least Jan 1, 2026
Steve O’LoughlinChief Financial Officer · Since at least Aug 12, 2026

Open People

Log in to ask 6ix AI your own questions about CNS Pharmaceuticals, Inc.